MVRBF - Infex's antibiotic MET-X gets FDA infectious disease product status

• Medivir ( OTC:MVRBF ) said the U.S. Food and Drug Administration (FDA) granted qualified infectious disease product (QIDP) designation to the company's partner Infex Therapeutics for MET-X.
• According to Infex, MET-X is a resistance bypass treatment which targets Gram-negative Enterobacterales. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics and evade antibiotic clearance of disease. MET-X blocks MBL resistance, restoring antibiotic activity.
• The drug is being developed to be one of the first broad-spectrum MBL inhibitors for a range of bacterial species and drug-resistant strains, according to Infex.
• Medivir said that MET-X is a broad spectrum Metallo-beta-lactamase inhibitor (MBLI) based on the MBLI program out-licensed by the company in 2017 to the AMR Centre, which changed its name to Infex in 2020.
• The drug is currently undergoing pre-clinical safety evaluation with clinical studies planned for 2023, Infex added.

For further details see: